

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/200858 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) *C12N 9/22* (2006.01)
A61K 31/7105 (2006.01) *C12N 15/10* (2006.01)
A61K 31/7115 (2006.01) *C12N 15/11* (2006.01)
A61K 31/7125 (2006.01) *C12N 15/55* (2006.01)
A61K 38/46 (2006.01) *C12N 15/85* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/000155

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,763 26 March 2021 (26.03.2021) US

(71) Applicant: **SPECIFIC BIOLOGICS INC.** [CA/CA]; 661 University Avenue, Suite 13066, Toronto, ON M5G 0B7 (CA).

(72) Inventor: **STEAD, Brent, E.**; 661 University Avenue, Suite 1300, Toronto, ON M5G 0B7 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: TARGETING ONCOGENIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE

FIG. 1

FIG. 1A




FIG. 1B

Other Gene Editors





FIG. 1C

TevCas



(57) Abstract: Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.

WO 2022/200858 A1

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*